CEO Wayne Huang described the company's performance as a shift toward higher-value products, noting that premium models like the T-Rex and Balance series are gaining traction despite supply constraints. While net losses widened from the US$7.7 million reported in the same quarter last year, management emphasized that working capital management remains a priority, with cash and cash equivalents reaching US$106.3 million by the end of June.
The company also announced the departure of board member Alain Lam, who stepped down to focus on his responsibilities at Xiaomi. Looking ahead, Zepp Health projects third-quarter 2026 revenue between US$68 million and US$73 million, banking on restored supply chains for its Bip and Helio Strap lines to improve unit economics and long-term profitability.
Comments (0)
No comments yet. Be the first!